Search

Displaying results 7771 - 7780 of 10000 in total
  1. Drug

    Lym-1-I-131

    go.drugbank.com/drugs/DB17445
    Experimental

    Lym-1-I-131 is a monoclonal antibody labeled with iodine-131 (131I) that preferentially targets malignant lymphocytes.

  2. Drug

    MK-0482

    go.drugbank.com/drugs/DB17453
    Investigational

    MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.

  3. Drug

    RO-7293583

    go.drugbank.com/drugs/DB17455
    Investigational

    RO-7293583 is a TYRP1-Targeting CD3 T-Cell Engager.

  4. Drug

    ETBX-011

    go.drugbank.com/drugs/DB17464
    Investigational

    ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).

  5. Drug

    Nanrilkefusp alfa

    go.drugbank.com/drugs/DB17480
    Investigational

    Nanrilkefusp alfa is a human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity binding sushi+ domain of IL-15 receptor alpha (IL-15Ra).

  6. Drug

    BI-765063

    go.drugbank.com/drugs/DB17482
    Investigational

    BI-765063 is a humanized IgG4 monoclonal antibody antagonist of signal regulatory protein α (SIRPα).

  7. Drug

    CGX-1321

    go.drugbank.com/drugs/DB17491
    Investigational

    CGX-1321 is a porcupine inhibitor that affects Wnt production and can block Wnt downstream signaling.[A257038]

  8. Drug

    SB 11285

    go.drugbank.com/drugs/DB17511
    Investigational

    SB 11285 is a second-generation Stimulator of Interferon Genes (STING) agonist.

  9. Drug

    Ligufalimab

    go.drugbank.com/drugs/DB17542
    Investigational

    Ligufalimab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen CD47. … It is under investigation in clinical trial NCT04900350 (A Trial of AK117 (Anti-cd47) in Patients With Myelodysplastic Syndrome).

  10. Drug

    FT-1101

    go.drugbank.com/drugs/DB17553
    Investigational

    FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor. … [A257301] FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies).